Results 271 to 280 of about 124,717 (304)
Some of the next articles are maybe not open access.
DNA repair and immune checkpoint blockade response
Cancer Genetics, 2022Immune checkpoint blockade (ICB) has shown immense promise for treating patients with various cancer types, but its effectiveness relies on our ability to identify likely responders. Here, we examined the association between mutations in 25 core DNA repair genes and ICB outcomes in 6619 patients across 9 cancer types with advanced disease and MSK ...
Jimmy A. Guo +7 more
openaire +2 more sources
Double immune checkpoint blockade in advanced NSCLC
Critical Reviews in Oncology/Hematology, 2020Immunotherapy-based options for patients with advanced non-small cell lung cancer (NSCLC) are increasing at an unprecedented pace, carrying the promise to prolong survival of this deadly disease. To maximize responses and extend benefit to a larger portion of patients, immunotherapy combination strategies are currently under investigation, with chemo ...
Mariniello A. +3 more
openaire +3 more sources
Adjuvant immune checkpoint blockade revisited
The Lancet Oncology, 2023Sahar Barjesteh, van Waalwijk van Doorn-Khosrovani +6 more
openaire +2 more sources
Microbiome dynamics in immune checkpoint blockade
Trends in Endocrinology & MetabolismImmune checkpoint blockade (ICB) is one of the leading immunotherapies, although a variable extent of resistance has been observed among patients and across cancer types. Among the efforts underway to overcome this challenge, the microbiome has emerged as a factor affecting the responsiveness and efficacy of ICB.
Chae Won Kim +2 more
openaire +2 more sources
Immune checkpoint blockades therapy of melanoma
Science Bulletin, 2023Hong, Liu +3 more
openaire +2 more sources
Immune Checkpoint Blockade in Metastatic Urothelial Cancer
Journal of Clinical Oncology, 2017The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches.
openaire +2 more sources
LIGHT May Improve Immune Checkpoint Blockade Response
Cancer Discovery, 2016Abstract A new study suggests that insufficient T-cell infiltration may explain why a majority of patients do not respond to immunotherapy. Combining PD-L1 inhibitors with antibody-guided LIGHT, a protein that recruits tumor-infiltrating lymphocytes, increased antitumor response in mice, and may have the potential to improve patient ...
openaire +2 more sources